Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
about
Atacicept: targeting B cells in multiple sclerosisB-cell survival factors in autoimmune rheumatic disordersFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsProfile of atacicept and its potential in the treatment of systemic lupus erythematosusClinical targeting of the TNF and TNFR superfamiliesManipulating B cell homeostasis: a key component in the advancement of targeted strategiesAn exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.A perspective on B-cell-targeting therapy for SLE.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.Atacicept as an investigated therapy for rheumatoid arthritis.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
P2860
Q24628925-47660151-BB87-4EFD-8F7D-FC8BF19CA976Q26796484-42F2A521-2FC9-4B78-B07C-0F257D17F8C8Q26822421-CBC1D694-3CC2-4D9A-AA23-077D9E56B293Q26849719-4F4B96E1-70BA-4D5E-B854-E9EBECD92DC6Q36762882-A5435D41-D560-4C06-9933-582E241C0401Q37177128-AA6EB1D3-BCAE-4B19-B48E-440355842D9AQ37328468-101BDB03-F9DC-4C58-AE16-686E1F897A44Q37400568-2785278E-27A9-4970-B4BB-8673A30F8A77Q37517575-E501BC9B-DFD1-463D-8918-32538329918DQ37577571-32314284-8620-4155-83DD-ED154BFC8F05Q37968620-2B4E0EF3-AB57-43FD-8E3D-742CB40D330CQ38060204-4A25E7E7-4F9A-40C4-A5CA-4C392B155CFDQ38235570-FF527EDB-76B0-4344-90FB-B96D6350C873Q38747383-569E63E7-2ECC-4D2A-A013-907E5207309CQ38801807-FD0A085F-9AE7-44D6-A044-880F2077317AQ40119794-275D2A30-2E13-452A-9EF4-7C4CE545FBA8Q41758222-3066CBA5-B21B-4C35-B4A5-3D43EDEA8777Q45937545-3691EB5B-74B2-4631-A656-2CB2D67210ACQ46071397-E6DD1E99-FF6A-4453-8951-9EF7B79791D5
P2860
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@en
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@nl
type
label
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@en
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@nl
prefLabel
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@en
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@nl
P2093
P1476
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
@en
P2093
Alain Munafo
Anthony Priestley
Ivan Nestorov
Jennifer Visich
Mark Rogge
P2888
P304
P356
10.1007/S00228-007-0311-7
P577
2007-05-01T00:00:00Z
P6179
1010770217